ebselen has been researched along with s 8932 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Easwaran, M; Manickam, M; Pillaiyar, T; Wendt, LL | 1 |
| Beccari, AR; Cannalire, R; Cerchia, C; Di Leva, FS; Summa, V | 1 |
| Cheng, Y; Claff, T; Gao, S; Gütschow, M; Jing, L; Kang, D; Liu, X; Müller, CE; Schäkel, L; Song, L; Sträter, N; Sylvester, K; Tavis, J; Tollefson, AE; Toth, K; Weiße, RH; Woodson, M; Yang, M; Ye, B; Zhan, P; Zhang, T | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Scudellari, M | 1 |
2 review(s) available for ebselen and s 8932
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans; Virus Internalization | 2021 |
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Topics: Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Structure; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2 | 2022 |
3 other study(ies) available for ebselen and s 8932
| Article | Year |
|---|---|
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Piperazines; Protease Inhibitors; SARS-CoV-2; Viral Nonstructural Proteins | 2022 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
The sprint to solve coronavirus protein structures - and disarm them with drugs.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Azoles; Betacoronavirus; China; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Papain-Like Proteases; Coronavirus RNA-Dependent RNA Polymerase; COVID-19 Vaccines; Cryoelectron Microscopy; Crystallization; Crystallography, X-Ray; Cysteine Endopeptidases; Drug Design; Drug Evaluation, Preclinical; Germany; High-Throughput Screening Assays; Humans; Isoindoles; Mice; National Institutes of Health (U.S.); Organoselenium Compounds; Peptidyl-Dipeptidase A; Protease Inhibitors; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Synchrotrons; Time Factors; United Kingdom; United States; Viral Nonstructural Proteins; Viral Proteins; Viral Vaccines | 2020 |